Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in south India

Clinical Infectious Diseases

Volumn 44, Issue 2, 2007, Pages 295-300

  Saghayam, Suneeta ^a,d   Kumarasamy, N ^a   Cecelia, Anitha J ^a   Solomon, Suniti ^a   Mayer, Kenneth ^b   Wanke, Christine ^c  

^a YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^b BROWN UNIVERSITY   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d The Voluntary Health Services Chennai   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ANTHROPOMETRY; ARTICLE; BODY BUILD; BODY COMPOSITION; BODY MASS; BODY WEIGHT; CD4+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; DRUG SUBSTITUTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPEDANCE; INDIA; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE; WAIST HIP RATIO; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INDIA; LAMIVUDINE; MALE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

EID: 33846128450     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/510491     Document Type: Article

References (17)

1. Ministry of Health and Family Welfare. NACO: estimation of HlV infection. National AIDS Control Organization. Available at: http://www.nacoonline.org/ facts_hivestimates04.htm.
2. Kuraarasamy N, Solomon S, Flanigan TP, Hemalatha R, Thyagarajan SP, Mayer KH. Natural history of human immunodeficiency virus disease in southern India. Clin Infect Dis 2003; 36:79-85.
3. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidy and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
4. Angerer T, Wilson D, Ford N, Kasper T. Access and activism: the ethics of providing antiretroviral therapy in developing countries. AIDS 2001; 15:581-90.
5. Wanke CA, Silva M, Forrester J, Speigelman D, Gorbach SL. Weight loss and wasting remain common complications in individuals infected with HIV in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 31:803-5.
6. Tang AM, Jacobson DL, Spiegelman D, Knox TA, Wanke C. Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-infected patients, 1995 to 2003. J Acquir Immune Defic Syndr 2005; 40:70-6.
7. Mwamburi DM, Wilson IB, Jacobson DL, et al. Understanding the role of HIV load in determining weight change in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:167-73.
8. Jacobson D, Knox T, Speigelman D, Skinner S, Gorbach S, Wanke C. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis 2005; 40:1837-45.
9. FRAM study. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40:121-31.
10. Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003; 32:48-56.
11. Callaway CW, Chumlea WC, Bouchard C, et al. Anthropometric standardization reference manual. Champaign, IL: Human Kinetics Books, 1988.
12. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach-2003 revision. Geneva: World Health Organization, 2003.
13. Ramachandran A, Snehalatha C, Kapur A, et al. High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia 2001; 44:1094-101.
14. Suneeta F, Gomathy S, Kumarasamy N, Purnima M, Solomon S. Assessment of the nutritional status of HIV/AIDS patients in an Indian tertiary care center [abstract P-92]. In: Program and abstracts of the 3rd International Conference on Nutrition and HIV Infection (Cannes, France). 1999.
15. Carbonnel F, Maslo C, Beaugerie L, et al. Effect of indinavir on HIV-related wasting. AIDS 1998; 12:1777-84.
16. Pujari SN, Dravid A, Naik Eknath, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in western India. J Acquir Immune Defic Syndr 2005; 39:199-202.
17. Mangili A, Murman DH, Zampini AM, Wanke C. Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the Nutrition for Healthy Living Cohort. Clin Infect Dis 2006; 42:836-42.